Steve Gavel Purchases 22,170 Shares of Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc. (NASDAQ:CABA) insider Steve Gavel bought 22,170 shares of the stock in a transaction dated Wednesday, January 21st. The stock was purchased at an average price of $2.27 per share, with a total value of $50,325.90. Following the acquisition, the insider owned 22,170 shares of the company’s stock, valued at $50,325.90. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Cabaletta Bio Stock Performance

Cabaletta Bio stock opened at $2.94 on Friday. Cabaletta Bio, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $3.67. The firm’s 50-day simple moving average is $2.30 and its 200 day simple moving average is $2.12. The stock has a market cap of $283.00 million, a PE ratio of -1.16 and a beta of 3.25.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.05. As a group, analysts predict that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Cabaletta Bio in a research note on Friday, October 10th. Jefferies Financial Group initiated coverage on shares of Cabaletta Bio in a report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target on the stock. Cantor Fitzgerald increased their price target on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CABA. CRA Financial Services LLC raised its stake in Cabaletta Bio by 36.4% in the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the period. Jones Financial Companies Lllp purchased a new position in shares of Cabaletta Bio in the third quarter worth about $47,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Cabaletta Bio in the second quarter valued at approximately $32,000. SG Americas Securities LLC lifted its stake in shares of Cabaletta Bio by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 30,629 shares of the company’s stock valued at $67,000 after buying an additional 9,365 shares in the last quarter. Finally, Comerica Bank boosted its holdings in Cabaletta Bio by 2,292.1% in the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after buying an additional 39,860 shares during the period.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average ~$2.24, increasing his stake to ~1.03M shares — a sizable insider buy from the company’s top executive. Read More.
• Positive Sentiment: Multiple other insiders (director Mark Simon, director Shawn Tomasello, insiders Steve Gavel, Gwendolyn Binder, David J. Chang, and General Counsel Michael Gerard) executed material purchases at ~$2.19–$2.28 per share — broad insider participation that signals management/board conviction. Read More.
• Positive Sentiment: Unusually large options activity: investors bought ~3,428 CABA call options (an ~83% increase vs. average daily call volume), consistent with short‑term bullish speculative interest.
• Positive Sentiment: Company program update coverage: reports say Cabaletta is accelerating its autoimmune CAAR‑T program and is targeting a 2027 FDA filing — a clear development roadmap that could materially de‑risk value if milestones are met. Read More.
• Neutral Sentiment: Analyst coverage remains skewed positive on the longer term (consensus “Moderate Buy” with an average price target well above current levels), but those price targets reflect successful clinical progress and are not guarantees. Read More.
• Neutral Sentiment: Institutional ownership moves reported previously show larger biotech investors increasing stakes — supportive for liquidity, but not an immediate catalyst.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.